+Vote!
ireland.com (Free subscription) | 02/12/2008
The company said the job cuts coupled with other measures would generate approximately $6 million in savings for 2009. The job losses equate to roughly a tenth of the workforce. The company expects a one-time exceptional cost of $600,000 following the changes. Chief executive Ronan O'Caoimh said he would forego 15 per cent of his salary with immediate effect and until further notice....
+Vote!
Market Wire - Pharmaceuticals and Biotech: Biotech (Free subscription) | 02/12/2008
Commenting on the announcement Ronan O'Caoimh, CEO, said, "Since my return as Chief Executive less than two months ago the Company has carried out a thorough review of its operations with a view to maximising future profitability. The reduction in the cost base which we are announcing today comes through a combination of headcount and overhead reductions and will significantly boost our...
+Vote!
Medical News Today (Free subscription) | 25/11/2008
... and a submission to the FDA will be filed simultaneously. Commenting on the success of the trials Ronan O' Caoimh, CEO, said, "The development of Destiny Max has been the largest development project ever undertaken by Trinity. It will enable Trinity to target the high throughput segment of the laboratory based haemostasis market which represents approximately 50% of the overall market...
+Vote!
Market Wire (Free subscription) | 24/11/2008
... and a submission to the FDA will be filed simultaneously. Commenting on the success of the trials Ronan O' Caoimh, CEO, said, "The development of Destiny Max has been the largest development project ever undertaken by Trinity. It will enable Trinity to target the high throughput segment of the laboratory based haemostasis market which represents approximately 50% of the overall market...
+Vote!
Market Wire - Pharmaceuticals and Biotech: Biotech (Free subscription) | 20/11/2008
... Biotech to six in total of which four are non-executive members. Commenting on the appointment, Ronan O'Caoimh, Chairman and CEO, said, "I am delighted to announce the appointment of Clint Severson to the Board of Trinity Biotech. With his vast array of experience and achievements in the diagnostics industry Clint represents a very strong addition to the Board." Forward-looking statements...
+Vote!
Market Wire (Free subscription) | 12/11/2008
... to explore strategic alternatives to enhance shareholder value. Commenting on the appointment Ronan O'Caoimh, Chairman and CEO, said, "Since my return as CEO of Trinity I have consistently stated my commitment to unlock shareholder value. The appointment of William Blair, a leading investment banking firm, represents the latest step in this process." Forward-looking statements in...
